Close X
Attorney Spotlight

How does Jessie Zeigler anticipate the intersection of privacy and smart technology will impact the future of litigation? Find out more>


Close X


Search our Experience

Experience Spotlight

Primary Care Providers Win Challenge of CMS Interpretation of Enhanced Payment Law

With the help and support of the Tennessee Medical Association, 21 Tennessee physicians of underserved communities joined together and retained Bass, Berry & Sims to file suit against the Centers for Medicare & Medicaid Services to stop improper collection efforts. Our team, led by David King, was successful in halting efforts to recoup TennCare payments that were used legitimately to expand services in communities that needed them. Read more

Tennessee Medical Association & Bass, Berry & Sims

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

GDPR Top 5 Actions You Should Take Now

The EU's General Data Protection Regulation (GDPR) went into effect on May 25th. As most organizations are aware, the GDPR applies not only to EU businesses but also many companies in the U.S. While the deadline is quickly approaching, most organizations are still grappling with the implications of the regulation on their business. Even if your readiness efforts are behind the curve, the GDPR Top 5 Actions You Should Take NOW will help you begin your efforts towards compliance and help mitigate your organization's risk in the short-term.

Click here to download the checklist.

Attorney Spotlight: Shannon Wiley

March 5, 2018

Shannon Wiley spotlightTell us about your practice.

I practice healthcare law almost exclusively in the "specialty drug and device" space. A specialty drug or device is generally any drug therapy that requires special treatment — for example, it is really expensive (i.e. over $100,000 for treatment), for a rare disease, has an odd treatment regime, or is difficult to get reimbursed by insurance. I spend a lot of my time assisting with strategic development of business relationships, like limited drug distribution networks, patient service offerings between manufacturers and pharmacies, as well as mergers and acquisitions. This includes helping to develop the relationships in accordance with regulations drafting the associated contracts.

What is an interesting trend happening right now related to your field of practice?

The specialty pharmacy market ebbs and flows with regard to M&A activity; we are in a flow right now. We are seeing private equity and vertical strategic buyers have the most interest. Private equity funds often look to aggregate pharmacies to create an enterprise with a sum greater than its parts, while vertical strategics bank on market synergies to increase asset value. It is fascinating to be a part of those acquisitions and later integration activities. It provides great insight into industry economic and supply chain trends. 

You've attended the Asembia Specialty Pharmacy Summit for several years. What do you always look forward to and enjoy about this event? 

During Asembia, the entire specialty industry converges in one spot. It is great opportunity to catch up with many industry colleagues (and really friends) that I often only get to see a couple of times a year. I also get to meet new people and learn about their businesses, which is always a delight. Also, each conference really develops its own voice. After the first or second day, one starts to hear that voice and get a feel for what is on peoples' minds at an industry level. It's a deep dive that is an absolute must for giving clients the industry insight and staying current.

Related Professionals

Related Services


Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.